Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Mode of Peroxisome Proliferator-Activated Receptor gamma Activation by Luteolin

Full text
Author(s):
Show less -
Puhl, Ana C. ; Bernardes, Amanda ; Silveira, Rodrigo L. [1] ; Yuan, Jing [2] ; Campos, Jessica L. O. ; Saidemberg, Daniel M. [3] ; Palma, Mario S. [3] ; Cvoro, Aleksandra [4] ; Ayers, Stephen D. [4] ; Webb, Paul [4] ; Reinach, Peter S. [2] ; Skaf, Munir S. [1] ; Polikarpov, Igor [5]
Total Authors: 13
Affiliation:
[1] Univ Estadual Campinas, Inst Quim, Campinas, SP - Brazil
[2] SUNY Coll Optometry, Dept Biol Sci, New York, NY 10010 - USA
[3] UNESP, Inst Biociencias, CEIS Dept Biol, Lab Biol Estrutural & Zooquim, Rio Claro, SP - Brazil
[4] Methodist Hosp, Res Inst, Houston, TX 77030 - USA
[5] Univ Sao Paulo, Inst Fis Sao Carlos, Dept Fis & Informat, BR-13566590 Sao Carlos, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: MOLECULAR PHARMACOLOGY; v. 81, n. 6, p. 788-799, JUN 2012.
Web of Science Citations: 53
Abstract

The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a target for treatment of type II diabetes and other conditions. PPAR gamma full agonists, such as thiazolidinediones (TZDs), are effective insulin sensitizers and anti-inflammatory agents, but their use is limited by adverse side effects. Luteolin is a flavonoid with anti-inflammatory actions that binds PPAR gamma but, unlike TZDs, does not promote adipocyte differentiation. However, previous reports suggested variously that luteolin is a PPAR gamma agonist or an antagonist. We show that luteolin exhibits weak partial agonist/antagonist activity in transfections, inhibits several PPAR gamma target genes in 3T3-L1 cells (LPL, ORL1, and CEBP alpha) and PPAR gamma-dependent adipogenesis, but activates GLUT4 to a similar degree as rosiglitazone, implying gene-specific partial agonism. The crystal structure of the PPAR gamma ligand-binding domain (LBD) reveals that luteolin occupies a buried ligand-binding pocket (LBP) but binds an inactive PPAR gamma LBD conformer and occupies a space near the beta-sheet region far from the activation helix (H12), consistent with partial agonist/antagonist actions. A single myristic acid molecule simultaneously binds the LBP, suggesting that luteolin may cooperate with other ligands to bind PPAR gamma, and molecular dynamics simulations show that luteolin and myristic acid cooperate to stabilize the Omega-loop among H2', H3, and the beta-sheet region. It is noteworthy that luteolin strongly suppresses hypertonicity-induced release of the pro-inflammatory interleukin-8 from human corneal epithelial cells and reverses reductions in transepithelial electrical resistance. This effect is PPAR gamma-dependent. We propose that activities of luteolin are related to its singular binding mode, that anti-inflammatory activity does not require H12 stabilization, and that our structure can be useful in developing safe selective PPAR gamma modulators. (AU)

FAPESP's process: 10/08680-2 - Molecular aspectos of lignocellulosic biomass degradation: dynamics of enzymes and plant cell wall nanoarchitecture
Grantee:Rodrigo Leandro Silveira
Support Opportunities: Scholarships in Brazil - Doctorate